TCM Biotech International (ROCO:4169) ROCE % : 3.05% (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is TCM Biotech International ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. TCM Biotech International's annualized ROCE % for the quarter that ended in Dec. 2023 was 3.05%.

TCM Biotech International ROCE % Historical Data

The historical data trend for TCM Biotech International's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TCM Biotech International ROCE % Chart

TCM Biotech International Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

2.31

5.88

0.65

3.98

2.81

TCM Biotech International Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															0.83	5.63	2.36	3.55	3.05

TCM Biotech International ROCE % Calculation

TCM Biotech International's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	24.804	/	( ( (862.872 - 224.843)	+	(1322.922 - 198.378) )	/ 2 )
	=	24.804	/	( (638.029	+	1124.544)	/ 2 )
	=	24.804	/	881.2865
	=	2.81 %

TCM Biotech International's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	26.906	/	( ( (854.883 - 215.3)	+	(1322.922 - 198.378) )	/ 2 )
	=	26.906	/	( ( 639.583	+	1124.544 )	/ 2 )
	=	26.906	/	882.0635
	=	3.05 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

TCM Biotech International (ROCO:4169) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

TCM Biotech International ROCE % Related Terms

Thank you for viewing the detailed overview of TCM Biotech International's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

TCM Biotech International (ROCO:4169) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TCM Biotech International Corp (ROCO:4169) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 97, Sec. 1, Xintai 5th Road, Xizhi District, Neihu District, Taipei, TWN, 221

Website

http://www.tcmbio.com

TCM Biotech International Corp is a Taiwan based biotechnology company. It is engaged in the research and development of therapeutics for the prevention and treatment of liver diseases. Its products includes Anti-adhesion System, Anti-neoplastic agents, Osteoporosis Treatment Preparation, Iron Preparations, Osteoarthritis (OA) Treatment Products, Urinary System Treatment Products and others. The company has a business presence in Taiwan and other international countries such as the United States, Japan, Singapore, Malaysia, Vietnam, the Philippines and China. The entity derives key revenue from the sales of multiple medical products which includes medicine, medical device, functional food and others.

TCM Biotech International (ROCO:4169) Headlines

No Headlines